RxDoctor Payments Data

Megan Mescher-Cox, DO

Internal Medicine · Oxnard, CANPI 1962794578

Payments from drug & device makers

$777in general payments, 2019–2025

Across 36 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$206
  • AbbVie$153
  • Pfizer$75
  • AstraZeneca$62
  • Gilead$58
  • Lilly USA, LLC$57
  • plus $166 from 5 others

What the payments were for

  • Food & beverage$777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$777 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$154,601
Medicare patients
306
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$45,738
OzempicSemaglutide54$45,366
EliquisApixaban38$41,013
JardianceEmpagliflozin37$30,736
JanuviaSitagliptin Phosphate27$28,033
TrulicityDulaglutide18$26,823
XareltoRivaroxaban23$26,003
FarxigaDapagliflozin Propanediol30$23,520
MyrbetriqMirabegron25$21,880
RybelsusSemaglutide12$20,069
Repatha SyringeEvolocumab14$12,815
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,837
Breo ElliptaFluticasone/Vilanterol20$9,123
SynthroidLevothyroxine Sodium51$4,047
Levothyroxine Sodium315$3,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$57$72,56158 claims
Novo NordiskOzempic, Rybelsus$45$65,43566 claims
PfizerEliquis$75$41,01338 claims
Boehringer IngelheimJardiance$36$30,73637 claims
AstraZenecaFarxiga$62$23,52030 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$21$23,32450 claims
AbbVieSynthroid$153$4,04751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oxnard

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →